Key Points
- Moderna President Stephen Hoge sold 53,336 shares on May 15 at an average price of $48.40, totaling about $2.58 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- After the transaction, Hoge still held 1,477,997 shares, valued at roughly $71.5 million, and his ownership fell by 3.48%. The article also notes he sold 160,009 shares in a separate trade in February.
- Moderna’s latest earnings missed profit expectations, reporting a loss of $3.40 per share versus estimates of a $3.02 loss, though revenue came in above forecasts at $389 million. Analysts currently have a consensus rating of “Reduce” with an average price target of $35.73.
Moderna, Inc. (NASDAQ:MRNA - Get Free Report) President Stephen Hoge sold 53,336 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $48.40, for a total transaction of $2,581,462.40. Following the sale, the president directly owned 1,477,997 shares in the company, valued at $71,535,054.80. This trade represents a 3.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Stephen Hoge also recently made the following trade(s):
- On Monday, February 23rd, Stephen Hoge sold 160,009 shares of Moderna stock. The shares were sold at an average price of $48.84, for a total transaction of $7,814,839.56.
Moderna Stock Performance
Shares of NASDAQ MRNA opened at $48.11 on Tuesday. The firm's 50-day moving average price is $51.45 and its 200-day moving average price is $41.12. The company has a quick ratio of 2.35, a current ratio of 2.41 and a debt-to-equity ratio of 0.08. The company has a market cap of $19.09 billion, a PE ratio of -5.90 and a beta of 1.05. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $59.55.
Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.02) by ($0.38). The company had revenue of $389.00 million for the quarter, compared to analysts' expectations of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The business's revenue was up 260.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($2.52) EPS. As a group, analysts anticipate that Moderna, Inc. will post -6.79 EPS for the current year.
Hedge Funds Weigh In On Moderna
Several institutional investors have recently made changes to their positions in the business. MUFG Securities EMEA plc bought a new stake in Moderna during the 2nd quarter worth approximately $28,000. Flagship Harbor Advisors LLC bought a new stake in Moderna during the 4th quarter worth approximately $31,000. Canton Hathaway LLC bought a new stake in Moderna during the 1st quarter worth approximately $31,000. Ameriflex Group Inc. raised its stake in Moderna by 3,775.0% during the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company's stock worth $32,000 after acquiring an additional 1,208 shares during the period. Finally, Cromwell Holdings LLC raised its stake in Moderna by 39.7% during the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company's stock worth $35,000 after acquiring an additional 341 shares during the period. Institutional investors own 75.33% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on the stock. Citigroup reaffirmed a "neutral" rating on shares of Moderna in a report on Monday, February 16th. Royal Bank Of Canada raised their price target on shares of Moderna from $35.00 to $38.00 and gave the company a "sector perform" rating in a report on Monday, May 4th. Morgan Stanley set a $33.00 price objective on shares of Moderna in a research note on Friday, May 1st. Barclays increased their price objective on shares of Moderna from $25.00 to $48.00 and gave the stock an "equal weight" rating in a research note on Thursday, April 2nd. Finally, The Goldman Sachs Group increased their price objective on shares of Moderna from $43.00 to $49.00 and gave the stock a "neutral" rating in a research note on Friday, May 1st. Two research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Reduce" and a consensus price target of $35.73.
Check Out Our Latest Stock Report on MRNA
Moderna Company Profile
(
Get Free Report)
Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.
Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
